A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 246 participants.

Also called NCT05260411

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 246 participants (enrolled count) (from the registry)
Sponsor
  • Akeso Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05260411
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05260411. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-26 (actual); primary completion 2022-12-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia
Condition
Hyperlipidemia
Intervention (Biological)
AK102
Intervention (Biological)
AK102
Intervention (Drug)
Placebo
Lead sponsor
Akeso (class: industry)

Record details

Record id
cardio:ct-nct05260411
Content hash
f0afc7d3b65ad86d5b7c4d16bdad818f305c2423115578a061850ab2ad1f59d6